Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
Disease progression was reduced in the first 3 months post-treatment period compared to the 3 months pre-treatment period, this...
top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
May 20, 20192 min
Kadimastem Announces Leadership Changes
NESS ZIONA, Israel, May 29, 2019 Kadimastem (TASE: KDST), a stem cell-based therapeutic company, announced recently that Yossi Ben Yosef...
Apr 18, 20192 min
Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®
Ness Ziona, Israel, April 18th 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the approval from the MOH of...
Mar 3, 20191 min
Appointment of a new CFO for Kadimastem
The Current CFO has accepted a position as the Director of the Budget Division of the Jewish Agency for Israel Ness Ziona, Israel, 3...
Feb 24, 20192 min
Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A
Ness Ziona, Israel, 24 February 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the completion of cell...
Feb 17, 20191 min
2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project
Ness Ziona, Israel, 17 February 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announces it has received approval for its...
Nov 27, 20181 min
Kadimastem to be included in the TASE Indices
Ness Ziona, Israel, November 27, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) received an announcement from the TASE, that...
Nov 14, 20181 min
Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M
Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces that, at the end of the exercise...
Nov 12, 20182 min
Kadimastem and Defymed Awarded Grant for the Development of a Product for the Treatment of Diabetes
Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces the approval by the European Union...
Nov 4, 20182 min
FDA Granted Kadimastem Orphan Drug Status for AstroRx® for the Treatment of ALS
The FDA grants orphan drug status to incentivize the development of one of a kind drugs and other medical treatments. This status grants...
Oct 9, 20183 min
Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem:
Ness Ziona, Israel, October 9, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces progress in the Phase 1 / 2a...
Oct 2, 20182 min
Altshuler Shaham and Company Stakeholders Lead $5.15 Million Investment in Kadimastem
Ness Ziona Science Park, Israel, October 2, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the completion of...
Jul 2, 20182 min
Kadimastem and The AFDR Selected to Receive a bi-National Grant
Ness Ziona, Israel, July 2nd 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the approval of the Australian...
Jul 1, 20181 min
Kadimastem has Upgraded its Manufacturing Site for Treatment of ALS Patients in the Clinical Trial
Kadimastem chose to upgrade the production rooms, for the treatment of ALS patients in the Phase 1 / 2a clinical trial, and adapt them to...
Jun 27, 20181 min
Kadimastem was honored with a prize for excellence for the presentation of the company's technology
Between June 20 and 22, 2018, European conference was held for ALS (ENCALS) at Oxford University in England. During the conference, the...
Jun 13, 20181 min
Initiation of coverage report on Kadimastem by global research firm Frost & Sullivan:
Report in English and a Hebrew summary https://maya.tase.co.il/reports/details/1167249/2/0 https://maya.tase.co.il/reports/details/116724...
Jun 6, 20183 min
Scientific Article by Kadimastem: Cell-Based Treatment for ALS was Published
Jun. 6, 2018 by a Prestigious Cell Therapy Scientific Journal Ness Ziona, Israel, 6 June 2018, Israeli biotechnology company Kadimastem...
May 15, 20181 min
Successful Public Offering for Kadimastem
May. 15, 2018 Ness Ziona, Israel, May 15, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces the completion of a...
Apr 26, 20182 min
Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients
Apr. 26, 2018 Ness Ziona, Israel, 26 April 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the enrollment of...
Apr 22, 20183 min
Kadimastem Collaborates with French SME Defymed to Validate a Combined Solution for Type 1 Diabetes
Ness Ziona, Israel, 22 April 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the signing of a memorandum of...
bottom of page